Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Schreij

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'Gerrit Schreij, Robert Janknegt
International Journal of STD & AIDS|January 23, 2003
Post-exposure prophylaxisMarchina E van der Ende, Rosa M Regez, Gerrit Schreij, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 18, 2008
Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohortI Marion de Boer-van der Kolk, Mirjam A G Sprangers, Marchina van der Ende, et al.
AIDS (London, England)|June 24, 2003
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsDavid Burger, Patricia Hugen, Peter Reiss, et al.
AIDS (London, England)|August 13, 2002
A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodiesValère J Goossens, Gerrit Schreij, Siebe van der Geest, et al.
Antiviral Therapy|September 14, 2010
Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the NetherlandsAnouk M Kesselring, Luuk Gras, Ferdinand W Wit, et al.
Therapeutic Drug Monitoring|January 28, 2003
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrationsDavid M Burger, Patricia W H Hugen, Rob E Aarnoutse, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|October 18, 2007
InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'Gerrit Schreij, Robert Janknegt
International Journal of STD & AIDS|January 23, 2003
Post-exposure prophylaxisMarchina E van der Ende, Rosa M Regez, Gerrit Schreij, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 18, 2008
Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohortI Marion de Boer-van der Kolk, Mirjam A G Sprangers, Marchina van der Ende, et al.
AIDS (London, England)|June 24, 2003
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsDavid Burger, Patricia Hugen, Peter Reiss, et al.
AIDS (London, England)|August 13, 2002
A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodiesValère J Goossens, Gerrit Schreij, Siebe van der Geest, et al.
Antiviral Therapy|September 14, 2010
Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the NetherlandsAnouk M Kesselring, Luuk Gras, Ferdinand W Wit, et al.
Therapeutic Drug Monitoring|January 28, 2003
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrationsDavid M Burger, Patricia W H Hugen, Rob E Aarnoutse, et al.
Pageof 1